p21(WAF1/CIP1) regulates the p300 sumoylation motif CRD1 through a C-terminal domain independently of Cyclin/CDK binding by Garcia-Wilson E & Perkins ND
©2
005
 LA
ND
ES 
BIO
SCI
EN
CE.
 DO
 NO
T D
IST
RIB
UT
E.
www.landesbioscience.com Cell Cycle 1113
[Cell Cycle 4:8, 1113-1119; August 2005]; ©2005 Landes Bioscience
Elisa Garcia-Wilson
Neil D. Perkins*
School of Life Sciences; Division of Gene Regulation and Expression; University of
Dundee; Dundee, Scotland; United Kingdom
*Correspondence to: Neil D. Perkins; School of Life Sciences; Division of Gene
Regulation and Expression; MSI/WTB Complex; Dow Street; University of Dundee;
Dundee, DD1 5EH;Scotland United Kingdom; Tel.: 44.1382.345.606; 
Fax: 44.1382.348.072; Email: n.d.perkins@dundee.ac.uk
Received 05/31/05; Accepted 06/01/05
Previously published online as a Cell Cycle E-publication:
http://www.landesbioscience.com/journals/cc/abstract.php?id=1885
KEY WORDS
transcription, cell cycle, PCNA, histone
deacetylases, HDAC, CBP, Sumo
ABBREVIATIONS
CRD1 cell cycle regulatory domain 1
CBP CREB binding protein
CDK cyclin dependent kinase
CKI CDK inhibitor
GST glutathione-s-transferase
HDAC histone deacetylase
PCR polymerase chain reaction
PCNA proliferating cell nuclear antigen
SAPK stress activated protein kinase
TSA Trichostatin A
ACKNOWLEDGEMENTS
We would like to thank all the members of the
NDP laboratory and the Division of Gene
Regulation and Expression at the University of
Dundee for their help and assistance, in particular
Dr T. Owen-Hughes. NDP is funded by a Royal
Society University Fellowship and E.G.W. was
funded by a BBSRC committee Ph.D. studentship.
Report
p21WAF1/CIP1 Regulates the p300 Sumoylation Motif CRD1
through a C-Terminal Domain Independently of Cyclin/CDK Binding
ABSTRACT
Although best known for its ability to inhibit Cyclin/Cdk complexes and the replication
protein PCNA, p21WAF1/CIP1 is a multifunctional protein that interacts with many cellular
binding partners, including a number of transcriptional regulators. Previously, we charac-
terized p21 de-repression of the p300 sumoylation-dependent transcriptional repression
domain, CRD1. Such repression domains are at least partially dependent upon recruitment
of histone deacetylase (HDAC) complexes but the mechanism through which p21 selectively
disrupts CRD1 activity remains unknown. Here, we demonstrate that distinct motifs in the
C-terminus of p21 are required for regulation of p300 CRD1 function and that this effect
does not correlate with Cyclin or PCNA binding. Through the creation of N-terminal
glutathione-s-transferase fusion proteins, which also overcome the problems of instability
that result from many p21 mutations, we investigated p21 binding to HDACs. Although
p21 binds both Class I and Class II HDACs in vitro, only weak association with HDAC1
and 2 is seen in cells. Mutation of the p21 PCNA binding domain significantly increases
this interaction suggesting that binding is mutually exclusive and only naturally occurs
under certain conditions. Binding of HDACs also failed to correlate with CRD1 inducibility,
suggesting that p21 targets other transcriptional repression complexes to mediate this effect.
INTRODUCTION
The p21WAF1/CIP CDK inhibitor (CKI) is a downstream effector molecule of many
cellular processes. These include p53 mediated cell cycle arrest, cellular differentiation and
senescence.5 Induction of p21 primarily occurs at the transcriptional level. For example,
in response to DNA damage or cell stress, the p53 tumor suppressor is stabilized, where-
upon it binds specific elements within the p21 promoter resulting in synthesis of p21
mRNA.6,7 p53 independent pathways regulating p21 transcription have been described,
particularly during cell differentiation.8,9 Although the induction of p21 during cell
senescence is only a transient elevation, it is an important step in this process.10 Proteolysis
is also an important regulator of p21 protein levels and this can be regulated by ubiquiti-
nation of p21.11
p21 is best known as an inhibitor of Cyclin/Cdk activities, the effect of which is cell
cycle arrest in G1/S or G2/M.
12 While this is undoubtedly a core function of p21, under-
lying many of its biological effects, it has also been demonstrated to have other important
regulatory activities. For example, at lower levels, p21 can function as a Cyclin/Cdk
complex assembly factor.13,14 Furthermore, p21 also binds proliferating cell nuclear antigen
(PCNA) a protein required for DNA polymerase recruitment to sites of DNA-replication
and repair.12 Binding of p21 to PCNA inhibits DNA replication and therefore contributes
to p21-mediated cell cycle arrest.12,15
Many other interactions of p21 have also been described and a number of these have
been found to exert transcriptional effects.16-18 For example, p21 has been described as
binding to and inhibiting the activities of E2F1 and c-Myc.19,20 Our laboratory has also
described a transcriptional activator function for p21 involving the p300 and CREB
Binding protein (CBP) coactivator proteins.1-3 p300 and CBP regulate a diverse array of
transcription factors, are acetyl transferases and can function to integrate multiple signalling
and gene expression pathways.21 Both proteins also have important functions as regulators
of the cell cycle and apoptosis.22 In addition, both are tumor suppressors targeted by many
viral oncoproteins and can be found mutated in tumors.23,24 Previously, our laboratory
discovered that both p300 and CBP contain a transcriptional repression domain, termed
CRD1, which becomes de-repressed in the presence of p21.3 Later, this domain was found
 
to contain two consensus sumoylation
sites and it was determined that sumoy-
lation was required for transcriptional
repression by CRD1.1 The CRD1
domain, when sumoylated, was found
to bind the histone deacetylase HDAC6
in vitro.1 Subsequently, sumoylation has
also been found to mediate HDAC-
dependent transcriptional repression by
Elk1.25 Although sumoylation can have
a plethora of biological effects, it is
emerging as a common mechanism of
transcriptional repression for a variety
of proteins.26
De-repression of the p300 CRD1
motif by p21 is a specific effect. For
example, our laboratory discovered that
p21 inducibility, but not CRD1
repression per se, is determined by the
core promoter sequence.2,3 Moreover,
p21 does not derepress the related
R-motif within the context of Elk1, but
does if this motif is inserted into
p300.27 Therefore, although sumoyla-
tion and HDAC recruitment appear to
be critical determinants of transcrip-
tional repression mediated by this class
of motif, there are other important
factors regulating specificity and
derepresssion. We are interested, there-
fore, in determining the mechanism
through which p21 can act to specifi-
cally de-repress the p300 CRD1 motif.
p21 can be thought of as having two
distinct functional domains. The N-
terminus binds Cyclin/Cdk complexes
through two discrete sites (the Cy1 and
Cdk motifs shown in Fig. 1A). The
N-terminus of p21 also binds E2F-120
and the pro-apoptotic proteins procas-
pase 3,28 stress activated protein kinase
(SAPK) and ASK.29 The C-terminus
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Figure 1. p21 mutagenesis. (A) Schematic
representation of the protein and p21 mutants
created. (B) Mutations in the C-terminus affect
expression levels of the protein. U-2 OS cells
were transfected with 5 µg of RSV expression
plasmid containing the indicated p21
variants. After 48 hours whole cell lysates
were prepared and immunoblotted with the
anti-p21 C-terminal antibody. The same results
are seen with an anti-N-terminal p21 anti-
body. (C and D) GST-tagged p21 proteins
express at similar levels. U-2 OS cells were
transfected with 5 µg RSV expression plasmid
containing empty GST vector or GST-p21
fusion proteins. After 48 hours whole cell
lysates were harvested. The proteins were
resolved by SDS-PAGE and immunoblotted
with anti-GST antibodies.
A
B
C
D
contains the binding sites for PCNA and several other proteins
(Fig. 1A). Significantly, many of these interactions appear to be
mutually exclusive with PCNA binding, such as the interaction with
c-Myc,30 PARP,31 or the HPV-16 E7 protein.32 This region also
contains a putative second Cyclin binding motif termed Cy2,33,34
and the bipartite nuclear localization sequence.35 Moreover, p21 is
phosphorylated within this region.36 p21 is reported to be phospho-
rylated by Akt/PKB, ZIP and Pim-1 kinases on Thr145 and PKCζ
on Ser146.37-40 These phosphorylation events have been reported to
disrupt the interaction between p21 and PCNA, stabilize the protein
and lead to its cytosolic retention.37,41 These modifications are also
through to contribute to the oncogenic functions of p21,42 since
cytosolic p21 can bind pro-apoptotic proteins like procaspase 3 and
inhibit their activity.43,44
Although our previous data suggested that regulation of the p300
CRD1 motif by p21 was independent of Cyclin/CDK inhibition
and did not involve p21 binding CRD1 directly2 the domains
actually required for this effect remained unknown. Here we have
determined which domains of p21 mediate this effect, developed a
method for overcoming the effects of p21 mutagenesis on protein
stability and discovered that p21 can bind histone deacetylases
(HDACs) in vitro and in cells.
MATERIAL AND METHODS
Antibodies. Antibodies used were anti-p21 C-terminus (Santa Cruz
sc-397), anti-p21 N-terminus (Oncogene OP64), anti-β-actin (Sigma
A5441), anti-GST (Amersham 27-4577-01), anti Cyclin B1 (Cancer
Research UK V152), anti-PCNA (Sigma P8825), anti-HDAC1 (CN
Biosciences PC544), anti-HDAC2 (Santa Cruz sc-6296), anti-HDAC3
(Cell Signalling 2632), anti-Cyclin D1 (BD Pharmigen 556470) and
anti-HDAC6 (Santa Cruz sc-11420).
Plasmids. All plasmids have been described previously1-3 except the GST
expression plasmid pEBGT which was obtained from Dario Alessi
(Dundee) and the C-terminal p21 mutants. For subcloning into pEBGT,
p21 inserts with an N-terminal BamHI site and C-terminal NotI site were
generated by PCR.
P21-N term. (pEBGT): GCTGGATCCATGTCAGAACCGGCTGG-
GGATGTCCG.
P21-C term. (pEBGT): GCTCGCCGGCGTTAGGGCTTCCTCTT-
GGAGAAG.
Similar primers were used to subclone p21 cDNAs into an RSV expression
vector, except that a HindIII was created at the N-terminus while a BamHI
site was used at the C-terminus. All C-terminal p21 mutants were created
by using extended C-terminal PCR primers, such that the entire mutant
p21 PCR product was created in one round of amplification. The
mCy1/Cy2 double mutant was created with mCy2 primers and using the
original mCy1 mutant as a template.
mPCNA primer: GCTTCTAGATTAGGGCTTCCTCTTGGAGAA-
GATCAGCCGGCGTTTGGAGTGGTACGCATCTGTCGCGCTG-
GTCGCCCGCCGTTTTCGACCC.
mCy2 primer: GCTTCTAGATTAGGGCTTCCTCTTGGAGAA-
GATCGCCCGGGCTTTGGAGTG.
A/A primer: GCTTCTAGATTAGGGCTTCCTCTTGGAGAAGATC -
AGCCGGCGTTTGGAGTGGTAGAAATCTGTCATGGCGGCCTGC-
CGCCGTTTTCGACCC.
D/D primer: GCTTCTAGATTAGGGCTTCCTCTTGGAGAAGAT-
CAGCCGGCGTTTGGAGTGGTAGAAATCTGTCATGTCGTCCTG-
CCGCCGTTTTCGACCC.
To create GST p21 (1-90) the p21 N-terminal primer from above was
combined with an internal antisense p21 primer that introduced a new stop
codon.
P21 antisense (1-90): GCTCGCCGGCGTTATCCCAACTCATCCC-
GGCCTCGCCG.
To create GST p21 (91-165) the p21 C-terminal primer from above was
combined with an internal sense p21 primer.
P21 sense (91-164): GCTGGATCCGGAGGAGGCAGGCGGCCTGGC.
GST-pull down from cell lysates. Whole cell lysates were prepared as
previously described4 and diluted with Buffer D (20 mM Hepes, 0.5 mM
DTT, 1 mM PMSF, 20% (v/v) glycerol and 0.1 µg/ml aprotonin, pepstatin
www.landesbioscience.com Cell Cycle 1115
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Figure 2. Subcellular localization of GST-p21 and GST-p21 mutants.
Immunofluorescence analysis of GST-fusions following transient transfection
of U-2 OS cells with 1.5 µg of the indicated GST-p21 expression plasmids.
and leupeptin) to 75 mM salt concentration.
NP-40 was added directly to a final concentra-
tion of 0.1%. Glutathione agarose was washed
twice in incubation buffer as before and incu-
bated with the cell extracts for 60 minutes at
4˚C. The beads were then spun down at 1000
rpm for 30 seconds and washed with incubation
buffer (20 mM Hepes pH 7.9, 75 mM KCl,
2.5 mM MgCl2, 1 mM DTT, 0.5 mM PMSF,
0.1% NP-40, 0.1 mg/ml aprotonin, pepstatin,
leupeptin and E64 protease inhibitors). This
was repeated twice and then the beads were
resuspended in SDS-loading buffer and loaded
onto a NuPage 4–12% gradient gel (Invitrogen).
Immunofluorescence microscopy. For
immunofluorescence, cells grown on coverslips
were fixed after washing once in PBS by incu-
bation in 3.7% formaldehyde/PBS (pH 6.8)
for 15 minutes. U-2 OS cells were permeabilized
in PBS-0.1% Triton X-100 for 15 minutes and
then blocked in PBS-0.05% Tween supple-
mented with 1% normal donkey serum for
30 minutes. Slides were stained with mouse
anti-GST antibody (1:500 dilution). The FITC
labelled secondary antibody was purchased from
Jackson Immunoresearch and used at 1:500
dilution. Appropriate controls were performed
with cells either stained with primary antibody
without secondary antibody to control for
auto-fluorescence or stained with secondary
antibody alone to control for background
staining. Cells were analysed and images were
acquired using a DeltaVision microscope.
Images were deconvoluted using SoftWorx
(Applied Precision).
Other assays. Transient transfections,
luciferase assays, protein extracts, GST pull downs
from recticulocyte lysates and western blots
were all performed as described previously.2,4
All transfections for luciferase assays were
performed a minimum of three times before calculating means and standard
deviations as shown in figures and contained appropriate levels of RSV or
CMV control plasmid such that each dish received the same amount of
DNA.
RESULTS
Mutagenesis of p21. To investigate the domains of p21 required for its
regulation of the p300 CRD1 motif, a series of mutations were introduced
into the full length human protein (Fig. 1A). In addition to mutations of the
Cyclin/CDK binding motifs previously described in the N-terminus of p21
(mCy1 and mCdk),2,20 mutations were also created in the PCNA binding
site (mPCNA), the putative second Cyclin binding site (mCy2) and the sites
previously shown to be phosphorylated by the Akt/PKB, ZIP, Pim-1 and
PKCζ kinases, Thr 145 and Ser146.37-40 In this latter case both phospho-
mimetic alterations in which Thr145 and Ser146 were mutated to aspartate
residues (D/D), and neutralizing mutations with these residues changed to
alanines (A/A) were generated. Both Thr145 and Ser 146 were mutated
simultaneously to avoid either residue becoming a substitute site for the
other, as previously reported.38 A further mutation in which both Cyclin
binding motifs were mutated (mCy1/Cy2) was also created.
Transient transfection of wild type and mutant p21 expression plasmids
into the human osteosarcoma cell line U-2 OS immediately revealed that a
number of mutations appeared to destabilize or inhibit p21 protein levels
(Fig. 1B). A similar result was seen irrespective of whether antibodies tar-
geting the N- or C-termini of p21 were used (not shown). Such differences
in expression levels would make an analysis of the effect of these mutations
on p300 CRD1 motif function difficult to interpret. Furthermore, while the
mCy1 and mCdk mutation did not affect p21 protein levels, they caused a
significant shift in p21 protein mobility (Fig. 1B) that did not result from
an error introduced into the cDNA (not shown). A similar shift in mobility
was also seen with the mCy2 mutation but creation of the double mCy1/
mCy2 mutation reversed this affect and resulted in p21 protein with normal
mobility. In addition, the mPCNA mutation resulted in a protein displaying
a mixture of both normal and reduced mobilities. The reason for these
mobility shifts was not determined but they suggest disruption of p21 protein
structure, even under the conditions of SDS-PAGE.
Recent work on the mechanism of degradation of p21 by the proteasome
has speculated that p21 might be modified on the N-terminal methionine
by an unknown ubiquitin ligase.11 By tagging p21 on the N-terminus with
a 6-x Myc tag, the stability of the protein was much increased.11 We therefore
investigated whether tagging p21 at the amino terminus would stabilize our
p21 mutants. We decided to use a tag that would also allow rapid purification
of p21 protein complexes and therefore used the pEBGT Glutathione
S-transferase (GST) mammalian expression vectors. All our C-terminal p21
mutants, together with mCy1 were recreated in this vector system.
Furthermore, we made two deletion mutants of p21 as GST fusions, GST
p21 (aa1-90) and GST p21 (aa91-164). All fusion proteins were now
expressed at an equivalent level to wild type GST p21 in U-2 OS cells
(Fig. 1C and D).
Since many of these mutations had the potential to interfere with the
nuclear targeting sequence of p21 we next investigated the subcellular
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Figure 3. De-repression of p300 CRD1 motif by GST p21 and GST p21 mutants. (A and B) Gal4 p300
N + mCRD1(15 ng) expression plasmid was cotransfected with Gal4 E1B reporter plasmid (1.5 µg) and
1.5 µg GST fusion proteins or 1.5 mg RSV p21 as indicated. Relative luciferase activity is shown.
A
B
localization of the GST p21 mutants. Immunofluorescence microscopy was
performed on U-2 OS cells transfected with GST-p21 fusions using an
anti-GST antibody. While transfected GST alone appears throughout the
cell GST-p21 is nuclear (Fig. 2). This is also true for all other GST p21
mutants except the GST-p21 D/D construct, which is almost exclusively
cytoplasmic. This result is consistent with previous observations41 and suggests
that phosphorylation of Thr145 and Ser146, in U-2 OS cells, regulates p21
localization. Interestingly, while many GST p21 images showed an increased
concentration of GST p21 around the nuclear periphery, GST p21 Cy1/
Cy2 appeared to have a more diffuse staining pattern throughout the nucleus.
Mutations in the C-terminus of p21 abrogate CRD1 de-repression. We
next examined whether any of these mutations inhibited p21 inducibility of
the p300 CRD1 motif. A luciferase reporter gene assay using a Gal4 p300
fusion protein, consisting of a truncated N-terminal version of p300 contain-
ing the CRD1 motif at the C-terminus has been previously used to study this
effect.1-3 Although the CRD1 motif has been shown to function in nonGal4
linked p300 and in the full length protein,1,3 using this simplified assay makes
interpretation of p21 effects easier, especially since Cyclin/CDK complexes
have been reported to bind the C-terminus of p300 and potentially regulate
histone acetyl transferase activity.45,46 Using this assay, we found that
GST-p21 was capable of de-repressing the CRD1 motif of p300, albeit at a
slightly reduced level (Fig. 3A). Consistent with our previous results,2 GST
mCy1 was also an efficient de-repressor of CRD1. Of our other mutants,
only the GST p21 A/A mutant (where Thr145 and Ser 146 are converted to
alanine) was capable of de-repressing CRD1. All other mutations failed to
induce the Gal4 p300 fusion protein to any significant degree. The failure
of the GST p21 D/D mutant most probably results from its cytoplasmic
localization (Fig. 2), a result that suggests that this function of p21 is a nuclear
event.
The failure of the mCy2 and mPCNA mutants (as well as mCy1/Cy2)
to de-repress CRD1 all confirmed that this was a function of the C-terminus
of p21. Previously, functional PCNA binding has been shown to require
only a small C-terminal p21 peptide.47 To see if this was also the case with
CRD1 de-repression, the functionality of the p21 deletion mutants was
examined. Neither p21 1-90 or 91-164 was able to de-repress CRD1 (Fig. 3B).
This suggested both that this effect is functionally distinct from PCNA
binding and also that it requires an extended region of the p21 C-terminus
or even the entire protein.
CRD1 de-repression does not correlate with Cyclin or PCNA binding.
We next used the GST p21 fusions to investigate the interaction of the wild
type and mutant proteins with known binding partners. HEK 293 cells,
where we have previously demonstrated p21 regulation of the p300 CRD1
motif3 were transfected with the GST-p21 expression plasmids. As expected,
purification of GST-p21 from cell lysates followed by SDS-PAGE and silver
staining revealed efficient purification of the GST target proteins (Fig. 4A).
Interestingly, a number of p21-associated proteins were also visible. Among
these, purifying in apparently stoichiometric quantities was a band correlating
with the molecular weight of PCNA. Analysis of the GST-p21 mutants, by
silver staining and western blot analysis, demonstrated that this band did
not copurify with either the mPCNA mutation or the D/D mutation
(which is cytoplasmic) (Figs. 4B and 5B). Western blot analysis of Cyclin B1
binding revealed that its interaction was efficiently inhibited by the mCy1
mutation (Fig. 4B). All other mutations did not interfere with Cyclin B1
binding, including the mCy2 mutation. Confusingly, however, the
mCy1/mCy2 double mutation also failed to prevent Cyclin B1 binding. The
reason for this is unclear. This protein still retains the CDK binding site in
the N-terminus and it is possible that the structural alterations seen with this
double mutation (Fig. 1B) result in this motif functioning with greater
efficiency. Similar results were seen with Cyclin D1 binding (Fig. 5B).
p21 interacts with histone deacetylases. Previously, it has been reported
that treatment with the histone deacetylase inhibitor trichostatin A (TSA)
partially reverses transcriptional inhibition by CRD1.1,3 In addition,
HDAC6 but not HDAC1 interacts with sumoylated CRD1 peptide in
vitro, while HDAC6 RNA interference partially reversed CRD1 repression
in cells.1 It was possible, therefore, that p21 de-repression of CRD1 might
result from binding and sequestering specific HDAC complexes. Analysis of
GST-p21 interactions in vitro demonstrated that this was a possibility, with
weak but specific binding being seen to HDAC1, HDAC4 and HDAC6
(Fig. 5A). This result was partially confirmed with purified GST-p21 proteins
expressed in HEK 293 cells. With wild type GST p21, virtually no binding
above background was seen with either HDAC1, 2, 3 or 6. In contrast, the
interaction of HDAC1 and 2 could be clearly observed with all p21 mutants
(Fig. 5B). In particular, the mPCNA mutant displayed particularly enhanced
levels of interaction, with HDAC3 association now also weakly seen. No
HDAC6 binding was seen, although this might reflect the reduced sensitivity
of this antibody. This enhanced binding seen with the mPCNA mutant did
not result from increased GST p21 expression levels but arose from an
overall increase seen in GST-p21 associated proteins, clearly visible by silver
staining (Fig. 5B). This suggests that the high level of PCNA binding
obscures many p21 protein:protein interactions and this fusion might be a
useful tool for the identification of other p21 binding partners. In particular,
it indicates that HDAC binding to p21 is mutually exclusive with both
PCNA binding and the interaction of other protein complexes. The binding
of HDACs to GST-p21 did not correlate with CRD1 inducibility. Therefore,
while this represents a useful tool for investigating p21 protein:protein inter-
actions in cells, we were not able to identify the binding partner for p21 that
mediates its effects on the p300 CRD1 motif.
DISCUSSION
De-repression of the p300 and CBP CRD1 motifs upon p21
expression is a unique transcriptional regulatory mechanism. Exactly
how CRD1 represses transcription and how this is inhibited by p21
remains unclear. Although CRD1 repression function was recently
identified as being dependent upon sumoylation of two
back-to-back consensus sites and to correlate, at least in part, with
HDAC recruitment,1 the mechanism through which p21 can regulate
this process is particularly obscure. The important role that this
pathway is likely to play is underscored by the critical roles both
p300/CBP and p21 play during the cell cycle, tumorigenesis, cellular
differentiation and senescence.5,22 The link between p21 and
www.landesbioscience.com Cell Cycle 1117
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Figure 4. Purification of p21 associated proteins from cell extracts. (A)
Analysis of GST and GST p21 associated proteins by SDS-PAGE and silver
staining. 15cm dishes of HEK 293 cells were transfected with the expression
plasmids for GST alone or GST-p21 fusion protein (4 µg per dish). After 48
hours the cells were harvested and whole cell lysates were prepared. These
were then subjected to incubation with glutathione agarose and the result-
ing complexes were purified and resolved by SDS-PAGE with subsequent sil-
ver staining. The position of GST and GST-p21 together with the band
hypothesized to be PCNA are indicated. (B) Western blot analysis of PCNA
and Cyclin B1 binding to GST p21 and GST p21 mutants. Protein extracts
were prepared and GST complexes purified and resolved by SDS PAGE
from transfected HEK 293 cells as in (A). The presence of PCNA and Cyclin
B1 was then determined by western blot analysis.
A B
p300/CBP was first established as a
result of effects on NF-κB transactiva-
tion seen upon p21 expression.46 More
recently, this link has been reinforced
and it has been suggested that p21
regulation of p300 is important for a
number of senescence associated,
NF-κB regulated, genes.17 p21 regula-
tion of the CRD1 motif is also pro-
moter specific,2 suggesting that the
physiological role of p21 regulation of
p300/CBP is to specifically target its
ability to regulate a subset of genes
under specific cellular circumstances.16
Here we have further investigated
the role of p21 protein in this process
and through a mutagenesis strategy
determined the structural motifs
required for its ability to regulate
CRD1. Initial attempts to create
mutants were problematic, since specific
point mutations were found to destabi-
lize the protein, making interpretation
of functional data impossible. This
problem was overcome by the use of
N-terminal GST fusions. These fusion
proteins were stable and importantly,
were still capable of de-repressing the
p300 CRD1 motif. Using these
mutants, we confirmed that p21 regu-
lation of CRD1 is not dependent upon
binding to Cyclins, a result implied
from our earlier studies.2 Furthermore,
although mutations in the C-terminus
of p21 do disrupt regulation of CRD1,
they also do not correlate with an ability
to bind PCNA. Unlike PCNA binding47
expression of a C-terminal p21 fragment
is not sufficient to regulate CRD1,
although in this case steric hindrance by the GST moiety cannot be
ruled out.
Since the repression function of the p300 CRD1 motif and other
sumoylated transcriptional repression domains has been linked to
interactions with histone deacetylases48 we next investigated if p21
were able to bind directly to HDACs. In this model, sequestration
of HDACs by p21 would result in CRD1 de-repression.
Interestingly, p21 did bind to a number of distinct Class I and Class
II HDACs, both in vitro and in cells. But this binding did not
correlate with CRD1 de-repression and in particular, no binding was
seen to HDAC6 in cell extracts, although an interaction in vitro was
observed. Furthermore, the binding of p21 to HDACs 1 and 2 in
HEK 293 cells was only revealed to any significant degree upon
mutagenesis. Here, loss of PCNA binding strongly stimulated this
interaction, implying mutually exclusive binding to p21. It is possible
therefore that the interaction of p21 with HDACs might only occur
under specific cellular circumstances when PCNA expression is
reduced.
It is possible that binding of p21 to an HDAC not investigated
here might hold the key to understanding its ability to regulate
CRD1. Furthermore, our previous observation that CRD1 is still
capable of repressing promoters where p21 de-repression does not 
operate,2 suggests multiple CRD1-sumo interacting corepressor
complexes with only a subset being subject to regulation by p21.
Other experiments we have performed suggest that HDACs are not
the only mechanism through which CRD1 and sumoylated repression
domains can repress transcription. While we have previously published
that the HDAC inhibitor TSA does relieve CRD1 repression,1 it is
only a partial effect and is very small relative to the de-repression seen
upon p21 expression or mutation of the sumoylation motifs directly1,3
(and data not shown). A possible explanation for this was provided
by a recent report linking the Sir2 related deacetylase SIRT1, to
p300 CRD1 function.49 SIRT1 is not inhibited by TSA but is inhib-
ited by nicotinamide.50,51 While we have also found that nicotinamide
can partially relieve CRD1 repression, either alone or in combination
with TSA, it can still not account for the strength of sumoylation
mediated transcriptional inhibition or the magnitude of the p21
effect, at least in U-2 OS cells (data not shown). Taken together, these
results all suggest that the majority of CRD1 mediated repression
occurs through a mechanism distinct to histone deacetylation and
that it is this that is targeted by p21. Through generating and char-
acterizing specific mutations that disrupt the ability of p21 to target
CRD1 repression, together with the demonstration that N-terminal
p21 fusion proteins remain functional for this effect, we now have
the tools to identify such a complex through a proteomic approach.
1118 Cell Cycle 2005; Vol. 4 Issue 8
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Figure 5. p21 interacts with histone deacetylases. (A) GSTp21 can bind HDACs in vitro. In vitro pull down
experiments were performed by incubating recombinant E. Coli expressed GST and GST-p21 with radiola-
belled, reticulocyte lysate translated, HDAC1, HDAC4, HDAC6, PCNA or luciferase. (B) Analysis of HDAC
binding to different GST p21 mutants. The experiment was performed as in Figure 4 above except GST p21
mutants were also included. Purified GST complexes were analysed either by silver staining or by western
blot analysis with the indicated antibodies.
A B
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